Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
You may also be interested in...
Merck's Emend Granted Broad Coverage Under Medicare Part B
The oral anti-emetic will be covered by Part B for first-line use in combination with dexamethasone and a 5-HT3 antagonist in patients receiving any of nine highly emetogenic chemotherapy agents under a final coverage decision memo. CMS loosens conditions for reimbursement in response to comments.
Merck's Emend Granted Broad Coverage Under Medicare Part B
The oral anti-emetic will be covered by Part B for first-line use in combination with dexamethasone and a 5-HT3 antagonist in patients receiving any of nine highly emetogenic chemotherapy agents under a final coverage decision memo. CMS loosens conditions for reimbursement in response to comments.
MedPAC To Examine Hospitals’ Handling Costs For Outpatient Drugs
Study will examine whether changes are needed to the outpatient prospective payment system. The Medicare Payment Advisory Commission also will investigate how comparative and cost-effectiveness data are used by payers other than Medicare.